MiMedx Group, Inc. (MDXG)
After hours:
| Previous close | 6.33 |
| Open | 6.34 |
| Bid | 6.13 x 400 |
| Ask | 6.17 x 100 |
| Day's range | 6.16 - 6.39 |
| 52-week range | 3.49 - 9.27 |
| Volume | |
| Avg. volume | 788,666 |
| Market cap | 905.261M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | 14.33 |
| EPS (TTM) | 0.43 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.50 |
GlobeNewswireMIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webc
- GlobeNewswire
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administratio
Simply Wall St.Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gain
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
